Your browser doesn't support javascript.
loading
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Dulucq, Stéphanie; Nicolini, Franck E; Rea, Delphine; Cony-Makhoul, Pascale; Charbonnier, Aude; Escoffre-Barbe, Martine; Coiteux, Valérie; Lenain, Pascal; Rigal-Huguet, Françoise; Liu, Jixing; Guerci-Bresler, Agnès; Legros, Laurence; Ianotto, Jean-Christophe; Gardembas, Martine; Turlure, Pascal; Dubruille, Viviane; Rousselot, Philippe; Martiniuc, Juliana; Jardel, Henry; Johnson-Ansah, Hyacinthe; Joly, Bertrand; Henni, Tawfiq; Cayssials, Emilie; Zunic, Patricia; Berger, Marc G; Villemagne, Bruno; Robbesyn, Fanny; Morisset, Stephane; Mahon, François-Xavier; Etienne, Gabriel.
Afiliação
  • Dulucq S; Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac, France; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France. stephanie.dulucq@chu-bordeaux.fr.
  • Nicolini FE; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; INSERM U1052, Centre de Recherche de Cancérologie de Lyon, Centre Léon Bérard, Lyon, France; Hematology department, Centre Léon Bérard, Lyon, France.
  • Rea D; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Adult Hematology Department, Hôpital Saint Louis, Paris, France.
  • Cony-Makhoul P; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department and Clinical Investigation Center, Centre Hospitalier Annecy-Genevois, Metz-Tessy, Pringy, France.
  • Charbonnier A; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Paoli-Calmettes, Marseilles, France.
  • Escoffre-Barbe M; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU de Pontchaillou, Rennes, France.
  • Coiteux V; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU Huriez, Lille, France.
  • Lenain P; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Henri Becquerel, Rouen, France.
  • Rigal-Huguet F; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Universitaire du Cancer, CHU de Toulouse, France.
  • Liu J; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology and Oncology department, Centre Hospitalier de Valence, Valence, France.
  • Guerci-Bresler A; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHRU Brabois, Nancy, France.
  • Legros L; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Ianotto JC; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Morvan Hospital, CHU, Brest, France.
  • Gardembas M; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU, Angers, France.
  • Turlure P; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU Dupuytren, Limoges, France.
  • Dubruille V; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Hôtel Dieu, Nantes, France.
  • Rousselot P; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier de Versailles, Le Chesnay, France.
  • Martiniuc J; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier de Saint Brieuc, France.
  • Jardel H; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier de Bretagne, Vannes, France.
  • Johnson-Ansah H; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Institute of Normandy, CHU de la Côte de Nacre, Caën, France.
  • Joly B; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CH Sud francilien, Corbeil-Essonne, France.
  • Henni T; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHR La Réunion, France.
  • Cayssials E; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU de Poitiers, Poitiers, France.
  • Zunic P; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier, Saint Pierre de La Réunion, France.
  • Berger MG; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology (Biology) department, CHU Estaing, Clermont-Ferrand, France.
  • Villemagne B; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Internal medicine and onco-hematology department, La Roche sur Yon, France.
  • Robbesyn F; Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac, France.
  • Morisset S; INSERM U1052, Centre de Recherche de Cancérologie de Lyon, Centre Léon Bérard, Lyon, France.
  • Mahon FX; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Bergonié, Bordeaux, France.
  • Etienne G; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Bergonié, Bordeaux, France.
Haematologica ; 107(12): 2859-2869, 2022 12 01.
Article em En | MEDLINE | ID: mdl-35615931
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide de Fase Crônica Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide de Fase Crônica Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França